Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1A | P35348 | 10/20 | 0.56 |
| ▸ | ADRA1B | P35368 | 9/20 | 0.56 |
| ▸ | ADRA1D | P25100 | 8/20 | 0.56 |
| ▸ | HTR1A | P08908 | 7/20 | 0.53 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.50 |
| ▸ | DRD2 | P14416 | 1/20 | 0.46 |
| ▸ | DRD3 | P35462 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL7518122 | 0.99 | ADRA1A (0.55) | ADRA1AADRA1BADRA1DHTR1ASLC6A4 | |
| SCHEMBL7528127 | 0.88 | HTR1A (0.68) | ADRA1AADRA1BADRA1DHTR1ADRD2 | |
| Bromide SCHEMBL7532131 | 0.87 | HTR1A (0.67) | ADRA1AADRA1BADRA1DHTR1ADRD2 | |
| SCHEMBL7527192 | 0.79 | HTR1A (0.62) | ADRA1AHTR1ADRD2DRD3 | |
| Bromide SCHEMBL7526692 | 0.78 | HTR1A (0.61) | ADRA1AHTR1ADRD2DRD3 | |
| SCHEMBL7532173 | 0.75 | ADRA1D (0.48) | ADRA1AADRA1BADRA1DHTR1A | |
| Bromide SCHEMBL7528092 | 0.74 | ADRA1D (0.48) | ADRA1AADRA1BADRA1DHTR1A | |
| SCHEMBL7528484 | 0.73 | ALDH1A1 (0.58) | HTR1ADRD2DRD3 | |
| Bromide SCHEMBL7519489 | 0.73 | ALDH1A1 (0.57) | HTR1ADRD2DRD3 | |
| SCHEMBL11679440 | 0.73 | ADRA1D (0.59) | ADRA1AADRA1BADRA1DHTR1ADRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020058666-A1 | 2-piperazinoalkylaminobenzoazole derivatives: dopamine receptor subtype specific ligands | NEUROGEN CORPORATION | 2002-05-16 | — | — | US | claimed |
| US-6284759-B1 | PSYCHOLOGICAL DISORDERS; NERVOUS SYSTEM DISORDERS | NEUROGEN CORPORATION | 2001-09-04 | — | — | US | claimed |
| US-6432958-B1 | FOR THERAPY AND PROPHYLAXIS OF NEUROPSYCHOLOGICAL DISORDERS SUCH AS SCHIZOPHRENIA, MANIA, DEMENTIA, DEPRESSION, ANXIETY, COMPULSIVE BEHAVIOR, SUBSTANCE ABUSE, MOTOR DISORDERS AND MOTION DISORDERS RELATED TO USE OF NEUROLEPTIC AGENT | NEUROGEN CORPORATION | 2002-08-13 | — | — | US | disclosed |
| US-20020058666-A1 | 2-piperazinoalkylaminobenzoazole derivatives: dopamine receptor subtype specific ligands | NEUROGEN CORPORATION | 2002-05-16 | — | — | US | disclosed |
| US-6284759-B1 | PSYCHOLOGICAL DISORDERS; NERVOUS SYSTEM DISORDERS | NEUROGEN CORPORATION | 2001-09-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020058666-A1 | 2-piperazinoalkylaminobenzoazole derivatives: dopamine receptor subtype specific ligands | CHRNA7, HTR7, OPRD1 | ADRA1A 74/4885ADRA1B 67/4885ADRA1D 83/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.